| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| DAPT (GSI-IX); DAPT (GSI-IX) | CFN60023 | 208255-80-5 | C23H26F2N2O4 = 432.46 | 5mg | QQ客服：2056216494 |
| 恩替诺特; Entinostat (MS-275) | CFN60024 | 209783-80-2 | C21H20N4O3 = 376.41 | 5mg | QQ客服：215959384 |
| 拉帕替尼; Lapatinib (GW572016) | CFN60025 | 231277-92-2 | C29H26ClFN4O4S = 581.06 | 5mg | QQ客服：215959384 |
| CHIR-99021 (CT99021); CHIR-99021 (CT99021) | CFN60026 | 252917-06-9 | C22H18Cl2N8 = 465.34 | 5mg | QQ客服：2159513211 |
| 盐酸多柔比星; Doxorubicin Hydrochloride | CFN60027 | 25316-40-9 | C27H29NO11.HCl = 579.98 | 5mg | QQ客服：2159513211 |
| XAV-939; XAV-939 | CFN60028 | 284028-89-3 | C14H11F3N2OS = 312.31 | 5mg | QQ客服：2056216494 |
| SB431542; SB431542 | CFN60029 | 301836-41-9 | C22H16N4O3 = 384.39 | 5mg | QQ客服：215959384 |
| 达沙替尼; Dasatinib (BMS-354825) | CFN60030 | 302962-49-8 | C22H26ClN7O2S = 488.01 | 5mg | QQ客服：3257982914 |
| 塞卡替尼; Saracatinib (AZD0530) | CFN60031 | 379231-04-6 | C27H32ClN5O5 = 542.03 | 5mg | QQ客服：1413575084 |
| PD0325901(Mirdametinib); PD0325901(Mirdametinib) | CFN60032 | 391210-10-9 | C16H14F3IN2O4 = 482.19 | 5mg | QQ客服：2159513211 |
| 帕比司他; Panobinostat (LBH589) | CFN60033 | 404950-80-7 | C21H23N3O2 = 349.43 | 5mg | QQ客服：3257982914 |
| 阿法替尼; Afatinib (BIBW2992) | CFN60034 | 439081-18-2 | C24H25ClFN5O3 = 485.94 | 5mg | QQ客服：215959384 |
| Selisistat; Selisistat (EX 527) | CFN60035 | 49843-98-3 | C13H13ClN2O = 248.71 | 5mg | QQ客服：2056216494 |
| 磷酸氯喹; Chloroquine diphosphate | CFN60036 | 50-63-5 | C18H32ClN3O8P2 = 515.86 | 5mg | QQ客服：2056216494 |
| 6-氨基-3-甲基嘌呤; 3-Methyladenine | CFN60037 | 5142-23-4 | C6H7N5 = 149.15 | 5mg | QQ客服：2056216494 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)